Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user experienced hair regrowth using a topical solution containing 5% minoxidil and 0.1% finasteride, despite an initial shedding phase. They reported no side effects and noted significant improvement in hair density, particularly around the crown area.

A user shared 14-month progress pictures using topical finasteride and minoxidil for hair loss. Others commented on the impressive results and asked about age, improvement timeline, and how to obtain finasteride.

The conversation is about the effectiveness and safety of a hair loss treatment called Pyri, with users discussing its availability and comparing it to other treatments like RU58841, fluridil, and alfatradiol. Some users are waiting for FDA approval before using Pyri, while others share their positive experiences with RU58841 and suggest additional treatments with minimal side effects.

A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.

A 23-year-old male used finasteride for 4.5 months and minoxidil with microneedling for over a year to combat hair loss. He experienced shedding but now sees noticeable hair regrowth and is pleased with the progress.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

A user shared a 4-month progress picture using Minoxidil twice daily and dermarolling once a week for hair loss. They plan to start finasteride soon and have experienced dry scalp and itching from the treatment.

A user shared progress pictures showing hair improvement after using 5% topical minoxidil for 8 months and 1mg oral finasteride for 4 months. The user is pleased with the results, noting less scalp exposure despite hair not being as thick as before.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The user switched from finasteride to dutasteride and oral minoxidil after experiencing side effects and worsening hair loss, which improved their condition. Dutasteride was preferred due to fewer side effects and better results compared to finasteride.

Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

A user's personal hair loss progress with treatments, including finasteride (1.25mg), minoxidil, needling, and Nizoral; and advice from other users on how to perform the needling correctly.

The user is documenting their hair loss journey, using oral finasteride since January 2025, and plans to add microneedling and rosemary oil. They have experienced no further hair loss but no gains, and are considering oral minoxidil due to having pets.

The user experienced significant hair regrowth after 9 months of using finasteride, with minimal use of minoxidil. They reported no side effects and emphasized patience and consistency in their treatment routine.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

An 18-year-old has been using oral finasteride for 4.5 months to address hair thinning noticed since Fall 2022. They report the back of their head feels thicker, but are unsure if it's due to actual progress or placebo effect.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

The user has been using finasteride, minoxidil foam, and microneedling for hair loss for four months. Some users suggest it's too early for noticeable results, while others note potential improvement and emphasize patience.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.